Literature DB >> 29142603

Expression and significance of secreted protein acidic and rich in cysteine in human osteosarcoma.

Yongkun Yang1, Xiaohui Niu1, Weifeng Liu1, Hairong Xu1.   

Abstract

Osteosarcoma is the most common primary malignancy of bone, and is a high-grade malignant mesenchymal tumor with high recurrence and metastatic rates. Increased expression of secreted protein, acidic and rich in cysteine (SPARC) indicates poor prognosis in a number of malignances. However, the expression level of SPARC in human osteosarcoma and its associated mechanism remains unclear. To analyze the expression of SPARC in human osteosarcoma and its potential application in the diagnosis and treatment of osteosarcoma, the clinical records and samples of 20 cases of osteosarcoma were collected. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis applied to detect SPARC expression levels in osteosarcoma tissues, with normal bone tissue as control. Immunofluorescence detection was used to examine the distribution of SPARC. The association between SPARC level and clinical factors was analyzed. RT-qPCR (P=0.002) indicated that the SPARC level in osteosarcoma tissues was significantly increased compared with that in normal tissues. Immunofluorescence detection indicated that SPARC was widely distributed in tumor tissues. SPARC protein expression level was positively associated with lung metastasis (P=0.016). The results indicated that SPARC tends to be highly expressed in human osteosarcoma tissues. The expression level of SPARC is associated with lung metastasis, which may be an indicator of prognosis. Thus, SPARC may be a potential tumor marker and therapeutic target in osteosarcoma.

Entities:  

Keywords:  biomarker; lung metastasis; osteosarcoma; secreted protein acidic and rich in cysteine

Year:  2017        PMID: 29142603      PMCID: PMC5666664          DOI: 10.3892/ol.2017.6871

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  46 in total

Review 1.  Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology.

Authors:  E Jendraschak; E H Sage
Journal:  Semin Cancer Biol       Date:  1996-06       Impact factor: 15.707

2.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.

Authors:  D Massi; A Franchi; L Borgognoni; U M Reali; M Santucci
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

3.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.

Authors:  S S Bielack; B Kempf-Bielack; U Heise; D Schwenzer; K Winkler
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

4.  Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.

Authors:  P J Paley; B A Goff; A M Gown; B E Greer; E H Sage
Journal:  Gynecol Oncol       Date:  2000-09       Impact factor: 5.482

Review 5.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

6.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Rolf A Brekken; Efthimios Sivridis; Kevin C Gatter; Adrian L Harris; E Helene Sage
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1.

Authors:  T F Lane; M L Iruela-Arispe; E H Sage
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

9.  Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

Authors:  Cindy L Schwartz; Richard Gorlick; Lisa Teot; Mark Krailo; Zhengjia Chen; Allen Goorin; Holcombe E Grier; Mark L Bernstein; Paul Meyers
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

10.  Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Authors:  Ian J Lewis; Marianne A Nooij; Jeremy Whelan; Matthew R Sydes; Robert Grimer; Pancras C W Hogendoorn; Muhammad A Memon; Simon Weeden; Barbara M Uscinska; Martine van Glabbeke; Anne Kirkpatrick; Esther I Hauben; Alan W Craft; Antonie H M Taminiau
Journal:  J Natl Cancer Inst       Date:  2007-01-17       Impact factor: 13.506

View more
  1 in total

1.  Vimentin, osteocalcin and osteonectin expression in canine primary bone tumors: diagnostic and prognostic implications.

Authors:  Camila Barbosa Amaral; Juliana da Silva Leite; Ana Beatriz Monteiro Fonseca; Ana Maria Reis Ferreira
Journal:  Mol Biol Rep       Date:  2018-07-31       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.